Royal Bank of Canada’s Scinai Immunotherapeutics SCNI Stock Holding History

Royal Bank of Canada’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Hold	0	–	–	–	7476
2024 Q1	–	Hold	0	–	–	–	7521
2023 Q4	–	Hold	0	–	–	–	7524
2023 Q3	–	Hold	0	–	–	–	7518
2023 Q2	–	Hold	0	–	–	–	7614
2023 Q1	–	Sell	-25	Closed	-$617	–	7418
2022 Q4	$1K	Hold	25	–	–	﹤0.01%	7076
2022 Q3	$2K	Hold	25	–	–	﹤0.01%	7062
2022 Q2	$3K	Hold	25	–	–	﹤0.01%	6852
2022 Q1	$4K	Hold	25	–	–	﹤0.01%	7335
2021 Q4	$6K	Hold	25	–	–	﹤0.01%	7191
2021 Q3	$6K	Hold	25	–	–	﹤0.01%	7092
2021 Q2	$7K	Hold	25	–	–	﹤0.01%	6984
2021 Q1	$10K	Hold	25	–	–	﹤0.01%	6816
2020 Q4	$7K	Sell	25 -11	-31%	-$13.3K	﹤0.01%	6541
2020 Q3	$141K	Buy	36 +2	+6%	+$7.68K	﹤0.01%	4769
2020 Q2	$78K	Sell	34 -1	-3%	-$1.61K	﹤0.01%	5003
2020 Q1	$27K	Buy	35 +26	+289%	+$23K	﹤0.01%	5424
2019 Q4	$8K	Hold	9	–	–	﹤0.01%	6227
2019 Q3	$5K	Hold	9	–	–	﹤0.01%	6039
2019 Q2	$5K	Hold	9	–	–	﹤0.01%	6322
2019 Q1	$5K	Hold	9	–	–	﹤0.01%	6272
2018 Q4	$4K	Hold	9	–	–	﹤0.01%	6248
2018 Q3	$5K	Hold	9	–	–	﹤0.01%	6275
2018 Q2	$6K	Hold	9	–	–	﹤0.01%	5994
2018 Q1	$5K	Buy	+9	New	+$5.62K	﹤0.01%	5934

Other funds holding SCNI

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

MSG

Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Royal Bank of Canada's SCNI Position: Q2 2024 in Review

Royal Bank of Canada held its Scinai Immunotherapeutics (SCNI) position steady in Q2 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7476.

Royal Bank of Canada first reported a position in SCNI in Q1 2018 and has held it in 20 quarters since. The position peaked at $141K in Q3 2020. 9 funds tracked by Wall St. Rank hold SCNI as of Q2 2024.

Royal Bank of Canada held 0 shares of Scinai Immunotherapeutics worth $0 as of Q2 2024.
Royal Bank of Canada left its Scinai Immunotherapeutics share count unchanged in Q2 2024.
Scinai Immunotherapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2024, its #7476 holding.
Royal Bank of Canada first reported a position in Scinai Immunotherapeutics in Q1 2018 and has held it in 20 quarters since.
Royal Bank of Canada's Scinai Immunotherapeutics position peaked at $141K in Q3 2020.
9 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2024.

Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.